OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs

by Richard E. Kast, Marc-Eric Halatsch, Rafael Rosell
Published 2021-05-01

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis

by Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K
Published 2019-01-01

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)

by Vázquez S, Casal J, Afonso Afonso FJ, Fírvida JL, Santomé L, Barón F, Lázaro M, Pena C, Amenedo M, Abdulkader I, González-Arenas C, Fachal L, Vega A
Published 2016-02-01

Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin

by Elli Narvi, Katri Vaparanta, Anna Karrila, Deepankar Chakroborty, Sakari Knuutila, Arto Pulliainen, Maria Sundvall, Klaus Elenius
Published 2018-11-01

Afatinib: new treatment options for lung cancer with activating EGFR mutations

by M. V. Stepanchenko, V. G. Zaitsev, S. L. Gutorov
Published 2015-12-01

Successful treatment of triple EGFR mutation T785A/L861Q/H297_E298 with afatinib

by Vito Longo, Annamaria Catino, Michele Montrone, Pamela Pizzutilo, Francesco Pesola, Ilaria Marech, Iolanda Capone, Arsela Prelaj, Domenico Galetta
Published 2021-07-01

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation

by Yosuke Miyashita, Ryo Ko, Naoko Shimada, Yoichiro Mitsuishi, Keita Miura, Naohisa Matsumoto, Tetsuhiko Asao, Takehito Shukuya, Rina Shibayama, Ryo Koyama, Kazuhisa Takahashi
Published 2021-02-01

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC

by Wu Z, Dai Y, Chen LA
Published 2019-10-01

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

by Wang Fen, Wang Shuhang, Wang Zhijie, Duan Jianchun, An Tongtong, Zhao Jun, Bai Hua, Wang Jie
Published 2012-08-01

Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features

by Yu XIAO, Xiang ZHU, Yangchun GU, Sen CHEN, Li LIANG, Baoshan CAO
Published 2018-03-01

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs 
in Lung Adenocarcinoma Patients with EGFR Gene Mutations

by Xiang ZHU, Li LIANG, Chen LIU, Wencheng YIN, Sen CHEN, Baoshan CAO
Published 2014-02-01

Treatment of Advanced NSCLC with Unknown EGFR Gene Status
__ TKI or Chemotherapy?

by Xiaoqing LIU, Jing XU
Published 2014-10-01

Lycopene minimizes skin toxicity and oxidative stress in patients treated with panitumumab-containing therapy for metastatic colorectal cancer

by Mauro Moroni, Marco Pirovano, Silvia Brugnatelli, Martina Zucca, Marco Morreale, Vittoria Rizzo, Alessandra Ferrari, Carmine Tinelli, Annalisa De Silvestri, Maurizio Meregalli, Monica Giordano, Salvatore Artale, Massimiliano Cergnul, Roberto Bollina, Mimma Rizzo, Paolo Pedrazzoli
Published 2021-08-01

The Efficacy and Safety of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Combined With Thymosin in Advanced Non-Small Cell Lung Cancer Patients Harboring Active Epider...

by Yongdong Feng, Guangkuo Zhu, Song Lang, Ping Hao, Guanghui Li, Fanglin Chen, Wenlei Zhuo, Yuzhong Duan, Anmei Zhang, Zhengtang Chen, Jianguo Sun
Published 2021-05-01

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs

by Taira Ninomaru, Akito Hata, Chiyuki Kokan, Hideaki Okada, Hirotaka Tomimatsu, Jun Ishida
Published 2021-03-01

Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report

by Diego Enrico, MD, Ludovic Lacroix, PharmD, PhD, Jeanne Chen, MD, Etienne Rouleau, PharmD, PhD, Jean-Yves Scoazec, MD, PhD, Yohann Loriot, MD, PhD, Lambros Tselikas, MD, Cécile Jovelet, PharmD, PhD, David Planchard, MD, PhD, Anas Gazzah, MD, Laura Mezquita, MD, PhD, Maud Ngo-Camus, MSc, Stefan Michiels, PhD, Christophe Massard, MD, PhD, Gonzalo Recondo, MD, PhD, Francesco Facchinetti, MD, Jordi Remon, MD, Jean-Charles Soria, MD, PhD, Fabrice André, MD, PhD, Gilles Vassal, MD, PhD, Luc Friboulet, PhD, Benjamin Besse, MD, PhD
Published 2020-06-01

Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer

by Kyu Sic You, Yong Weon Yi, Jeonghee Cho, Jeong-Soo Park, Yeon-Sun Seong
Published 2021-06-01

El cáncer de pulmón en mujeres

by Enriqueta Felip
Published 2015-06-01

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer

by Hua Ye, Yi Liu, Kefeng Wu, Hui Luo, Liao Cui
Published 2020-07-01